関連する実験動画
Updated: Feb 22, 2026

10:36
Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
20.9K
生きた生物治療薬IBP-9414 (L. reuteri) が,出生体重が非常に低い乳児に投与された:関連性研究
Josef Neu1, Teresa Del Moral2, Scott O Guthrie3,4
1University of Florida College of Medicine, Gainesville, FL, USA. neuj@peds.ufl.edu.
Pediatric research
|February 20, 2026
まとめ
生きた生物治療薬IBP-9414 (L. reuteri) は,出生時体重が非常に低い (VLBW) 乳児に対する安全性を実証しました. NECや栄養耐性を低下させなかったが,この脆弱な集団における全原因死亡率を大幅に低下させた.
科学分野:
- 新生児医学 新生児医学
- マイクロバイオーム・セラピュティクス
- 胃腸の健康について
背景:
- 非常に低出生体重 (VLBW) の乳児は,死亡率と腸内合併症の高いリスクに直面しています.
- 末性腸炎 (NEC) と栄養不耐症は,VLBWの幼児ケアにおける重要な課題です.
研究 の 目的:
- VLBWの乳児におけるIBP-9414 (L. reuteri) の有効性と安全性を評価する.
- IBP-9414が死滅性腸球炎 (NEC),持続栄養耐性 (SFT),全原因死亡率に与える影響を評価する.
主な方法:
- 2158人のVLBWの乳児を対象とした前向きの,ダブルブラインド,プラセボ対照のフェーズ3試験です.
- ランダム化1:1で,出生から34 6/7週間の月経後の年齢まで毎日IBP-9414またはプラセボを受けます.
- プライマリエンドポイントは,NEC発生率とSFTまでの時間;二次エンドポイントは,全因死亡率でした.
主要な成果:
- IBP-9414は,プラセボと比較して,NEC発生率 (RR: 0.85) やSFTまでの時間 (HR: 1.10) を有意に減少させなかった.
- IBP-9414 (6.2%対8.5%; RR: 0.73,p=0.036) で全原因死亡率の統計的に有意な減少が観察されました.
- 不良事象の発生率は,グループ間で類似しており,IBP-9414バクテレミアの証拠はありませんでした.
結論:
- IBP-9414治療は,VLBWの乳児にとって安全です.
- この研究は,IBP-9414がVLBWの乳児の死亡率を低減する可能性を裏付けています.
- 研究結果は,IBP-9414が腸内結末を改善し,この脆弱な集団における死亡率を下げる可能性があることを示唆しています.
関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
943
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
943
Bioequivalence studies: Biowaivers
306
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
306
Drug Dosing: Infants and Children
371
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
950
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
950

